APCCC 2022 | Mediating toxicities associated with mHPSC treatment

Andrew Armstrong, MD, MS, Duke Cancer Institute, Durham, NC describes how many therapies for mHSPC such as abiraterone with prednisone, though life-prolonging, have detrimental side effects. The cardiovascular system and musculoskeletal system are commonly affected, as well as the mental health of patients. Prof. Armstrong outlines strategies clinicians may adopt to overcome these survivorship challenges, such as emphasizing regular exercise, monitoring bone density, and home monitoring of blood pressure. This interview took place at the APCCC 2022 conference, held in Lugano, Switzerland.